Sponsor

Merrimack Pharmaceuticals

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name Merrimack Pharmaceuticals appears in 15 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials15
Recruiting shown0
Roles2
SourceClinicalTrials.gov
Advertisement

Clinical trials

15 shown
A Study Evaluating MM-310 in Patients With Solid TumorsNCT03076372 · lead sponsor · 2017-02-22
UNKNOWN
Phase 1 Combination Study of MM-151 With MM-121, MM-141, or TrametinibNCT02538627 · lead sponsor · 2015-08-01
TERMINATED
MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer PatientsNCT02213744 · lead sponsor · 2014-07-01
TERMINATED
Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary TreatmentNCT01520389 · lead sponsor · 2012-01-01
COMPLETED
A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced CancersNCT01451632 · lead sponsor · 2011-10-01
COMPLETED
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast CancerNCT01421472 · lead sponsor · 2011-08-01
COMPLETED
Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast CancerNCT01304797 · lead sponsor · 2011-03-01
UNKNOWN
A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast CancersNCT01209195 · lead sponsor · 2010-10-01
COMPLETED
Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast CancerNCT01151046 · lead sponsor · 2010-06-01
COMPLETED
MM-111 in Combination With Herceptin in Patients With Advanced Her2 Amplified, Heregulin Positive Breast CancerNCT01097460 · lead sponsor · 2010-04-01
COMPLETED
A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung CancerNCT00994123 · lead sponsor · 2010-02-01
COMPLETED
A Study of MM-111 in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive CancersNCT00911898 · lead sponsor · 2009-06-01
COMPLETED
A Phase 2 Study to Evaluate the Efficacy and Safety of 60mg of MM-093 in Patients With Active Rheumatoid ArthritisNCT00458146 · lead sponsor · 2007-02-01
COMPLETED
Efficacy Study of MM-093 in Rheumatoid Arthritis Patients on Methotrexate (MTX)NCT00105976 · lead sponsor · 2005-02-01
COMPLETED
A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLCNCT02387216 · collaborator · 2015-02-01
TERMINATED

Sponsor roles

lead sponsor14
collaborator1
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.